Suven Life sciences announces Phase 3 Clinical Trial of SUVN-502 (Masupirdine)

Suven Life Sciences today informing that our NCE SUVN-502 (Masupirdine), a potent, selective, brain penetrant and orally active, novel chemical entity has planned initiation of global Phase 3 clinical trial for the treatment of Agitation and aggression in Alzheimer's type dementias with expected enrollment of patients from middle of September 2021. This multi-center study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result expected by the end of year 2024.

"Progression of SUVN-502 (Masupirdine) into Phase 3 clinical development is a significant achievement and milestone in enhancing our clinical pipeline. Our lead molecules address niche areas of cognitive impairment associated with neurodegenerative disorders", said Venkat Jasti, CEO of Suven Life Sciences.

SUVN-502 (Masupirdine), a lead clinical candidate having undergone phase 2 study on 564 patients for moderate Alzheimer's disease without meeting primary end point. After an in-depth analysis of the data and intense dialogue with key opinion leaders, we have planned a new Clinical Trial for the treatment of Agitation and aggression in Alzheimer's type dementias.

Prior to the initiation of Phase 2A study, SUVN-502 has successfully undergone two phase 1 studies in Switzerland and USA on 122 healthy young and elderly male populations with no major adverse events and no serious adverse events.

Shares of Suven Life Sciences Ltd. was last trading in BSE at Rs. 78.7 as compared to the previous close of Rs. 80.65. The total number of shares traded during the day was 46545 in over 957 trades.

The stock hit an intraday high of Rs. 80.6 and intraday low of 78. The net turnover during the day was Rs. 3703315.

Source : Equity Bulls

Keywords